tranexamic acid has been researched along with Thrombophlebitis in 10 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).
Excerpt | Relevance | Reference |
---|---|---|
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 7.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
" A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 3.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
"Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors." | 2.70 | Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (50.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bistervels, IM | 1 |
Scheres, LJJ | 1 |
Hamulyák, EN | 1 |
Middeldorp, S | 1 |
Martínez Rodríguez, E | 1 |
Mato, M | 1 |
Otero, J | 1 |
Ferri, JR | 1 |
Gonzálvez, A | 1 |
Torres, LM | 1 |
Gelmers, HJ | 1 |
Lindoff, C | 1 |
Rybo, G | 1 |
Astedt, B | 1 |
Hiippala, ST | 1 |
Strid, LJ | 1 |
Wennerstrand, MI | 1 |
Arvela, JV | 1 |
Niemelä, HM | 1 |
Mäntylä, SK | 1 |
Kuisma, RP | 1 |
Ylinen, JE | 1 |
Santagostino, E | 1 |
Morfini, M | 1 |
Rocino, A | 1 |
Baudo, F | 1 |
Scaraggi, FA | 1 |
Gringeri, A | 1 |
Hedlund, PO | 1 |
Verstraete, M | 1 |
Endo, Y | 2 |
Nishimura, S | 2 |
Miura, A | 2 |
Iwamoto, K | 1 |
Itoh, T | 1 |
Kuwayama, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.[NCT00378872] | 132 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
The Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin / Hematocrit in Isolated Operative Posterior Wall Acetabular Fractures: a Prospective, Randomized, Double-blinded, Multicenter Study[NCT05357079] | Early Phase 1 | 98 participants (Anticipated) | Interventional | 2017-08-25 | Recruiting | ||
Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
Intervention | units (Median) |
---|---|
The Placebo Group | 2 |
The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
Intervention | participants (Number) |
---|---|
Tranexamic Group | 15 |
Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Group | 2 |
Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
Intervention | units (Number) |
---|---|
Tranexamic Group | 38 |
Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
Intervention | milliliter (Median) |
---|---|
Tranexamic Group | 520 |
Placebo Group | 730 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 0 |
Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
Intervention | Total Blood Loss (mL) (Mean) |
---|---|
Tranexamic Acid | 1122.4 |
Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
Intervention | mL (Mean) |
---|---|
Tranexamic Acid | 221 |
Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
Intervention | g (Mean) |
---|---|
Tranexamic Acid | 154.6 |
Normal Saline | 200.1 |
2 reviews available for tranexamic acid and Thrombophlebitis
Article | Year |
---|---|
Sex matters: Practice 5P's when treating young women with venous thromboembolism.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low- | 2019 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
4 trials available for tranexamic acid and Thrombophlebitis
Article | Year |
---|---|
Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid.
Topics: Adult; Aged; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middle Aged; Recurrence; Subarachnoi | 1980 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; | 1997 |
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi | 2001 |
Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test.
Topics: Acute Disease; Aged; Clinical Trials as Topic; Dextrans; Fibrinogen; Heparin; Humans; Male; Middle A | 1975 |
4 other studies available for tranexamic acid and Thrombophlebitis
Article | Year |
---|---|
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss, | 2006 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura.
Topics: Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Humans; Male; Purpura, Thrombocytopenic; Throm | 1988 |
[Idiopathic thrombocytopenic purpura, associated with deep vein thrombosis induced by tranexamic acid].
Topics: Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Male; Purpura, Thrombocy | 1988 |